Domov › Kronična limfocitna levkemija › Massachusetts › Boston
Klinične študije za Kronična limfocitna levkemija v Boston, MA
31 študij za Kronična limfocitna levkemija išče udeležence na lokacijah v Boston in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Vključevanje udeležencevFaza 1/2
- Dana Farber Cancer Institute, Boston
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Vključevanje udeležencevFaza 3
- Dana-Farber Cancer Institute, Boston
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Vključevanje udeležencevFaza 3
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Vključevanje udeležencevFaza 1/2
- Dana Farber Cancer Institute, Boston
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Vključevanje udeležencevFaza 3
- Dana Farber Cancer Institute, Boston
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Vključevanje udeležencevFaza 3
- Beth Israel Deaconess Medical Center (Bidmc), Boston
- Dana Farber Cancer Institute, Boston
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Vključevanje udeležencevFaza 3
- Dana Farber Cancer Institute, Boston
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
Vključevanje udeležencevFaza 2
- Dana-Farber Cancer Institute, Boston
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Vključevanje udeležencevFaza 1/2
- Research Site, Boston
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Vključevanje udeležencevFaza 1
- Tufts Medical Center, Boston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Vključevanje udeležencevFaza 1/2
- Massachusetts General Hospital, Boston
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Vključevanje udeležencevFaza 4
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL
Vključevanje udeležencevFaza 2
- Massachusetts General Hospital, Boston
Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
Vključevanje udeležencevFaza 2
- Research Site, Boston
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
Vključevanje udeležencevFaza 1Vabljeni zdravi prostovoljci
- Brigham and Women's Hospital, Boston
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Vključevanje udeležencevFaza 2
- Boston Medical Center, Boston
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Vključevanje udeležencevOpazovalna študija
- Dana-Farber Cancer Institute, Boston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Vključevanje udeležencevFaza 1
- Dana Farber Cancer Institute, Boston
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
Vključevanje udeležencevOpazovalna študija
- Dana-Farber Cancer Institute, Boston
Understanding Chronic Lymphocytic Leukemia
Vključevanje udeležencevOpazovalna študija
- Dana Farber Cancer Institute, Boston
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
Vključevanje udeležencevFaza 2Vabljeni zdravi prostovoljci
- DFCI/BWH Brigham and Women's Hospital, Boston
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Vključevanje udeležencevFaza 4
- Dana-Farber Cancer Institute, Boston
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Vključevanje udeležencevFaza 4
- Dana-Farber Cancer Institute, Boston
Study of SGR-1505 in Mature B-Cell Neoplasms
Vključevanje udeležencevFaza 1
- Beth Israel Deaconess Medical Center, Boston
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
Vključevanje udeležencevFaza 1/2
- Dana-Farber Cancer Institute, Boston
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Vključevanje udeležencevFaza 2
- Dana-Farber Cancer Institute /ID# 230061, Boston
Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
Vključevanje udeležencevFaza 2
- Beth Israel Deaconess Medical Center, Boston
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
Vključevanje udeležencevFaza 2
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Mosunetuzumab for CLL MRD Clearance
Vključevanje udeležencevFaza 1/2
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
Vključevanje udeležencevFaza 2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
Vključevanje udeležencevFaza 1
- Dana-Farber Cancer Institute, Boston
Študije za Kronična limfocitna levkemija v drugih mestih
- Columbus, OH28 študij
- Durham, NC27 študij
- Washington, DC22 študij
- Seattle, WA20 študij
- Rochester, MN18 študij
- New York City, NY18 študij
- Houston, TX17 študij
- Baldwin Park, CA16 študij
- Milwaukee, WI15 študij
- Chicago, IL14 študij
- Cincinnati, OH14 študij
- Nashville, TN13 študij
Druge študije v Boston
- Rak dojke112 študij
- Nemalicelični pljučni rak90 študij
- Rak (vse vrste)85 študij
- Metastatski rak63 študij
- Kolorektalni rak63 študij
- Rak pljuč62 študij
- Rak jajčnikov61 študij
- Rak prostate59 študij
- Depresija52 študij
- Rak endometrija50 študij
- Srčno popuščanje44 študij
- Akutna mieločna levkemija44 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.